Antibody Cocktail Battles Botulism

Join Our Community of Science Lovers!


On supporting science journalism

If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.


Researchers have developed a potent weapon against the paralyzing disease botulism. The affliction results from exposure to botulinum neurotoxin (BoNT), which is secreted by a soil bacterium called Clostridium botulinum. The most poisonous substance known, just a gram of BoNT could kill a million people if evenly dispersed and inhaled. As such, it ranks among the Centers for Disease Control and Prevention¿s six highest-risk threat agents for bioterrorism. At the moment, no anti-botulism treatments capable of being produced on a large scale are available. But a new drug described in a report published online this week by the Proceedings of the National Academy of Sciences both neutralizes the toxin very effectively in mice and apparently can be readily mass-produced and stockpiled.

The drug consists of three antibodies, each of which binds to a different part of the botulinum toxin. Together they squelch far more of the toxin than they would individually. "This approach has allowed us to develop a drug consisting of only a few antibodies which neutralizes toxin better than the most potent natural immune response," says team member James D. Marks of the University of California at San Francisco. And because the antibody genes are cloned into a manufacturing cell line, cultured cells could conceivably churn out an unlimited supply of the antibodies.

So far, the researchers have shown the drug to work in mice against one of the four BoNT types known to cause botulism. But they suspect that such cocktails of multiple antibodies, or oligoclonal Abs, will one day combat a wide array of diseases caused by other pathogens and biologic threat agents. Indeed, the team concludes that its findings support "the rapid development and evaluation of oligoclonal Ab for countering BoNT and other agents of biowarfare and bioterrorism."

Kate Wong is an award-winning science writer and senior editor for features at Scientific American, where she has focused on evolution, ecology, anthropology, archaeology, paleontology and animal behavior. She is fascinated by human origins, which she has covered for nearly 30 years. Recently she has become obsessed with birds. Her reporting has taken her to caves in France and Croatia that Neandertals once called home to the shores of Kenya’s Lake Turkana in search of the oldest stone tools in the world, as well as to Madagascar on an expedition to unearth ancient mammals and dinosaurs, the icy waters of Antarctica, where humpback whales feast on krill, and a “Big Day” race around the state of Connecticut to find as many bird species as possible in 24 hours. Wong is co-author, with Donald Johanson, of Lucy’s Legacy: The Quest for Human Origins. She holds a bachelor of science degree in biological anthropology and zoology from the University of Michigan. Follow her on Bluesky @katewong.bsky.social

More by Kate Wong

It’s Time to Stand Up for Science

If you enjoyed this article, I’d like to ask for your support. Scientific American has served as an advocate for science and industry for 180 years, and right now may be the most critical moment in that two-century history.

I’ve been a Scientific American subscriber since I was 12 years old, and it helped shape the way I look at the world. SciAm always educates and delights me, and inspires a sense of awe for our vast, beautiful universe. I hope it does that for you, too.

If you subscribe to Scientific American, you help ensure that our coverage is centered on meaningful research and discovery; that we have the resources to report on the decisions that threaten labs across the U.S.; and that we support both budding and working scientists at a time when the value of science itself too often goes unrecognized.

In return, you get essential news, captivating podcasts, brilliant infographics, can't-miss newsletters, must-watch videos, challenging games, and the science world's best writing and reporting. You can even gift someone a subscription.

There has never been a more important time for us to stand up and show why science matters. I hope you’ll support us in that mission.

Thank you,

David M. Ewalt, Editor in Chief, Scientific American

Subscribe